uniQure N.V.

QURENASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
26.45 USD
↘ 1.54 (5.50%)AT CLOSE (11:59 AM EDT)
26.60
↗ 0.15 (0.56%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
26.60
↗ 0.15 (0.56%)
🔴Market: CLOSED
Open?$27.63
High?$28.19
Low?$26.30
Prev. Close?$27.99
Volume?1.5M
Avg. Volume?1.9M
VWAP?$26.93
Rel. Volume?0.75x
Bid / Ask
Bid?$22.95 × 100
Ask?$30.03 × 100
Spread?$7.08
Midpoint?$26.49
Valuation & Ratios
Market Cap?1.8B
Shares Out?63.1M
Float?55.9M
Float %?89.4%
P/E Ratio?N/A
P/B Ratio?11.82
EPS?-$3.31
Dividend?0.00%
Ex-Dividend?N/A

QURE is currently priced at $26.54. The technical outlook is "Neutral" and the fundamental picture shows "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
221
Market Cap
1.9B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.uniqure.com
Listed
2014-02-05
Address
PAASHEUVELWEG 25A
AMSTERDAM, 1105 BP
Phone: 1-339-970-7000
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
1
Momentum?
65
Short Sent.?
51
Piotroski F-Score?3/9Weak
Altman Z-Score?-0.70Distress
Confidence?57%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?18.43%High
Short Interest?10.3M
Days to Cover?4.0
Free Float55.9M
Avg Daily Volume2.6M
Settlement Date2026-05-15
Financial Health
Current Ratio?10.40Strong
Quick Ratio?10.40Strong
Cash Ratio?2.36Strong
Debt/Equity?0.33Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
N/A▾
P/B?
Peers
100
S&P
16
11.82HIGH▾
P/S?
Peers
100
S&P
3
97.57HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-9.8CHEAP▾
EV/Sales?
Peers
100
S&P
3
92.59HIGH▾
Returns & Efficiency
ROE?
S&P
3
-139.9%WEAK▾
ROA?
S&P
3
-26.8%WEAK▾
Cash Flow & Enterprise
FCF?$-172559000
Enterprise Value?$1.7B
Fundamentals ratios updated end of day
MarketsMoversWatchlist